Gene Expression Signatures for Predicting Prognosis of Squamous Cell and Adenocarcinomas of the Lung

Abstract

Non-small-cell lung cancers (NSCLC) compose 80% of all lung carcinomas with squamous cell carcinomas (SCC) and adenocarcinoma representing the majority of these tumors. Although patients with early-stage NSCLC typically have a better outcome, 35% to 50% will relapse within 5 years after surgical treatment. We have profiled primary squamous cell lung carcinomas from 129 patients using Affymetrix U133A gene chips. Unsupervised analysis revealed two clusters of SCC that had no correlation with tumor stage but had significantly different overall patient survival (P = 0.036). The high-risk cluster was most significantly associated with down-regulation of epidermal development genes. Cox proportional hazard models identified an optimal set of 50 prognostic mRNA transcripts using a 5-fold cross-validation procedure. Quantitative reverse transcription-PCR and immunohistochemistry using tissue microarrays were used to validate individual gene candidates. This signature was tested in an independent set of 36 SCC samples and achieved 84% specificity and 41% sensitivity with an overall predictive accuracy of 68%. Kaplan-Meier analysis showed clear stratification of high-risk and low-risk patients [log-rank P = 0.04; hazard ratio (HR), 2.66; 95% confidence interval (95% CI), 1.01-7.05]. Finally, we combined the SCC classifier with our previously identified adenocarcinoma prognostic signature and showed that the combined classifier had a predictive accuracy of 71% in 72 NSCLC samples also showing significant differences in overall survival (log-rank P = 0.0002; HR, 3.54; 95% CI,). This prognostic signature could be used to identify patients with early-stage high-risk NSCLC who might benefit from adjuvant therapy following surgery. (Cancer Res 2006; 66(15): 7466-72)

Impact of chemotactic factors and receptors on the cancer immune infiltrate: a bioinformatics study revealing homogeneity and heterogeneity among patient cohorts

“…Five different datasets were included for several major cancer types, in particular breast carcinoma (TCGA consortium), 31–34 colorectal carcinoma (http://www.intgen.org or TCGA consortium), 35,36 non-small cell lung carcinoma (TCGA consortium) 37–40 and melanoma, 41–45 to study the correlation between the expression level of metagenes indicating the presence of immune cell types and a variety of chemotactic factors and receptors. An extra dataset concerning breast carcinoma 46 was used for studying expression variability and treatment response.…”

Expression Profiles of Loneliness-associated Genes for Survival Prediction in Cancer Patients

“…Many studies have developed useful gene signatures by examining only the gene profiling data of the patient specimens that they can access (Lu et al, 2006;Raponi et al, 2006;Beer et al, 2002).…”

936 Quantitative genome-wide methylation analysis of high-grade non-muscle invasive bladder cancer

“…76 Reduced transcript expression in a tumor was defined where expression was at least 3-fold lower than the mean level of expression observed in control samples; the converse was true for increased transcript expression. 37,38,77 Non-array informatics and statistics STATA (version 8, Stata Corporation, College Station, TX) was used to analyze methylation and gene expression data in tumor and normal cohorts using Fisher's exact tests (frequency of methylation), Student's t-tests (mean level of methylation), and Spearman correlation coefficients (associations between methylation and gene expression). P-values <0.05 were considered statistically significant.…”